ERBB3 and cancer: A meta-analysis study linking HER3 overexpression and survival in solid tumors (using the data from immunohistochemistry) revealed the median percentage of cancers with HER3 overexpression was 42.2% and HER3 was associated with worse overall survival (OS) at both the 3 year and the 5 year period [74].